Indoco Remedies Ltd

Indoco Remedies Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Indoco Remedies Ltd

₹ 339 -0.04%
04 Jul - close price
indoco.com BSE: 532612 NSE: INDOCO
About

Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).[1]

Key Points

Business Segments
A) Domestic Formulations (48% of FY24 revenue)[1]
Indoco Remedies Ltd holds a strong foothold across various therapeutic categories, including Gastroenterology, Dentistry & Stomatology, Respiratory, Diabetology, Women's Health, Nutritional Products, Cardiology, Metabolic Disorders, and Primary Care medicines. In FY24, the domestic business crossed 1,280 Cr, ranking 31st in India (IQVIA MAT 2023-24). The company enjoys prescription patronage from over 240,000 prescribers, with 106 million prescriptions annually, and ranks 22nd in the Indian Pharmaceutical Market (IQVIA). It has 45 products ranking among the top 5 in their respective sub-segments.

Website BSE NSE
  • Market Cap ₹ 3,124 Cr.
  • Current Price ₹ 339
  • High / Low ₹ 388 / 190
  • Stock P/E
  • Book Value ₹ 120
  • Dividend Yield 0.44 %
  • ROCE 2.76 %
  • ROE -0.86 %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

  • Stock is trading at 2.83 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 6.54% over past five years.
  • Company has a low return on equity of 7.63% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
409 408 433 399 427 423 473 449 445 401 397 373 347
328 337 345 337 363 360 401 384 388 350 344 353 344
Operating Profit 80 71 88 62 64 63 72 65 57 52 53 20 3
OPM % 20% 17% 20% 15% 15% 15% 15% 15% 13% 13% 13% 5% 1%
0 1 0 0 0 0 1 -5 24 4 4 5 6
Interest 3 4 5 7 9 8 8 10 11 12 15 14 16
Depreciation 18 20 16 17 18 20 21 23 24 24 25 25 25
Profit before tax 60 48 67 38 38 36 44 27 46 20 17 -13 -31
Tax % 32% 20% 26% 26% 34% 27% 25% 26% 19% 23% 26% -23% -15%
40 38 50 28 25 26 33 20 38 15 13 -10 -26
EPS in Rs 4.38 4.17 5.39 3.02 2.75 2.81 3.60 2.17 4.07 1.62 1.39 -1.11 -2.84
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
726 851 1,005 1,072 1,038 968 1,106 1,240 1,540 1,667 1,791 1,518
606 686 834 915 903 891 982 1,016 1,212 1,380 1,532 1,390
Operating Profit 120 165 171 157 135 77 124 224 328 286 259 128
OPM % 17% 19% 17% 15% 13% 8% 11% 18% 21% 17% 14% 8%
2 2 1 4 5 6 2 3 2 1 19 19
Interest 19 10 12 6 24 21 26 22 14 25 37 57
Depreciation 31 47 61 63 68 72 71 73 79 71 88 98
Profit before tax 72 109 99 91 48 -9 29 131 236 192 153 -7
Tax % 20% 24% 17% 15% 15% -69% 16% 30% 35% 26% 24% 18%
58 83 82 77 41 -3 24 92 155 141 117 -9
EPS in Rs 6.28 8.99 8.93 8.41 4.47 -0.31 2.63 10.03 16.77 15.34 12.65 -0.95
Dividend Payout % 22% 18% 18% 19% 22% -97% 11% 15% 13% 15% 12% -21%
Compounded Sales Growth
10 Years: 6%
5 Years: 7%
3 Years: 0%
TTM: -15%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -109%
Stock Price CAGR
10 Years: -1%
5 Years: 11%
3 Years: -3%
1 Year: -2%
Return on Equity
10 Years: 9%
5 Years: 10%
3 Years: 8%
Last Year: -1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 18 18 18 18 18 18 18 18 18 18 18 18
Reserves 439 500 558 633 657 643 662 750 886 1,009 1,108 1,085
91 94 139 280 282 296 262 267 257 333 514 754
178 229 224 266 280 301 330 281 327 300 320 344
Total Liabilities 726 842 939 1,197 1,238 1,258 1,272 1,317 1,488 1,660 1,961 2,201
325 339 373 440 489 468 590 570 555 661 732 799
CWIP 44 63 55 91 136 185 51 68 122 113 114 181
Investments 0 1 18 3 3 2 2 2 2 20 59 52
356 439 493 664 611 603 630 676 809 866 1,055 1,169
Total Assets 726 842 939 1,197 1,238 1,258 1,272 1,317 1,488 1,660 1,961 2,201

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
100 110 112 88 123 132 123 82 174 179 177 91
-41 -88 -113 -171 -135 -104 -56 -67 -121 -209 -302 -260
-58 -21 0 132 -39 -16 -64 -30 -44 23 122 169
Net Cash Flow 1 1 -0 50 -51 12 3 -14 8 -7 -3 -0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 69 66 68 73 73 73 69 69 70 77 83 90
Inventory Days 147 179 173 188 204 209 230 245 248 228 207 299
Days Payable 94 145 137 167 158 195 184 119 108 89 79 121
Cash Conversion Cycle 122 100 103 95 119 88 115 195 210 217 211 267
Working Capital Days 73 77 79 80 77 64 56 107 113 120 125 158
ROCE % 17% 21% 17% 12% 7% 1% 6% 16% 23% 17% 12% 3%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
58.69% 58.68% 58.68% 58.69% 58.73% 58.75% 58.75% 58.72% 58.76% 58.76% 58.80% 58.90%
1.17% 1.19% 1.23% 1.55% 1.58% 1.59% 1.69% 1.92% 1.48% 1.70% 1.25% 1.24%
18.07% 17.97% 18.07% 18.06% 17.93% 17.79% 19.56% 19.41% 18.67% 18.25% 18.91% 18.75%
22.07% 22.16% 22.00% 21.69% 21.75% 21.87% 20.00% 19.92% 21.07% 21.27% 21.02% 21.02%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.03% 0.03% 0.03% 0.09%
No. of Shareholders 38,49838,07235,71334,73135,43136,58832,60033,20134,51134,41634,67634,497

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls